Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

122 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Relevance, Risks, and Benefits of Early-Phases Clinical Trials Participations for Patients With Hematological Malignancies From 2008 to 2023.
Guerra M, Alouani E, Hueso T, Ouali K, Danu A, Hollebecque A, Bahleda R, Willekens C, Gazzah A, Baldini C, Postel-Vinay S, Micol JB, Massard C, De Botton S, Ribrag V, Michot JM. Guerra M, et al. Among authors: bahleda r. Eur J Haematol. 2025 Jan;114(1):89-97. doi: 10.1111/ejh.14307. Epub 2024 Sep 21. Eur J Haematol. 2025. PMID: 39305190 Free PMC article.
Is Local Ablative Stereotactic Radiation Therapy a Valuable Rescue Strategy for Time on Drug in Patients Enrolled in Phase I Trials?
Mavrikios A, Baldini C, Loriot Y, Hénon C, Marabelle A, Postel-Vinay S, Champiat S, Danlos FX, Quevrin C, Lopes E, Gazzah A, Bahleda R, Massard C, Deutsch E, Levy A. Mavrikios A, et al. Among authors: bahleda r. Int J Radiat Oncol Biol Phys. 2024 Dec 1;120(5):1245-1256. doi: 10.1016/j.ijrobp.2024.07.2336. Epub 2024 Aug 10. Int J Radiat Oncol Biol Phys. 2024. PMID: 39128580
Exploring the Role of Target Expression in Treatment Efficacy of Antibody-Drug Conjugates (ADCs) in Solid Cancers: A Comprehensive Review.
Mathiot L, Baldini C, Letissier O, Hollebecque A, Bahleda R, Gazzah A, Smolenschi C, Sakkal M, Danlos FX, Henon C, Beshiri K, Goldschmidt V, Parisi C, Patrikidou A, Michot JM, Marabelle A, Postel-Vinay S, Bernard-Tessier A, Loriot Y, Ponce S, Champiat S, Ouali K. Mathiot L, et al. Among authors: bahleda r. Curr Oncol Rep. 2024 Oct;26(10):1236-1248. doi: 10.1007/s11912-024-01576-9. Epub 2024 Jul 27. Curr Oncol Rep. 2024. PMID: 39066847 Review.
Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.
Facchinetti F, Loriot Y, Brayé F, Vasseur D, Bahleda R, Bigot L, Barbé R, Nobre C, Combarel D, Michiels S, Italiano A, Smolenschi C, Tselikas L, Scoazec JY, Ponce-Aix S, Besse B, André F, Olaussen KA, Hollebecque A, Friboulet L. Facchinetti F, et al. Among authors: bahleda r. Clin Cancer Res. 2024 Nov 1;30(21):4943-4956. doi: 10.1158/1078-0432.CCR-24-1834. Clin Cancer Res. 2024. PMID: 39226398 Free PMC article.
Evaluating Debio 1347 in Patients with FGFR Fusion-Positive Advanced Solid Tumors from the FUZE Multicenter, Open-Label, Phase II Basket Trial.
Grivas P, Garralda E, Meric-Bernstam F, Mellinghoff IK, Goyal L, Harding JJ, Dees EC, Bahleda R, Azad NS, Karippot A, Kurzrock R, Tabernero J, Kononen J, Ng MCH, Mehta R, Uboha NV, Bigot F, Boni V, Bowyer SE, Breder V, Cervantes A, Chan N, Cleary JM, Dhawan M, Eefsen RL, Ewing J, Graham DM, Guren TK, Won Kim J, Koynov K, Oh DY, Redman R, Yen CJ, Spetzler D, Roubaudi-Fraschini MC, Nicolas-Metral V, Ait-Sarkouh R, Zanna C, Ennaji A, Pokorska-Bocci A, Flaherty KT. Grivas P, et al. Among authors: bahleda r. Clin Cancer Res. 2024 Oct 15;30(20):4572-4583. doi: 10.1158/1078-0432.CCR-24-0012. Clin Cancer Res. 2024. PMID: 38771739 Clinical Trial.
Association of Lung Immune Prognostic Index (LIPI) with Disease Control Rate and Progression-Free Survival in Patients with Soft-Tissue Sarcoma Treated with Immunotherapy in Early-Phase Trials.
Zoghbi M, Patel BA, Roulleaux Dugage M, Mezquita L, Bahleda R, Dufresne A, Brahmi M, Ray-Coquard I, Pautier P, Blay JY, Le Cesne A, Massard C, Besse B, Auclin E, Nassif Haddad EF. Zoghbi M, et al. Among authors: bahleda r. Cancers (Basel). 2024 Dec 3;16(23):4053. doi: 10.3390/cancers16234053. Cancers (Basel). 2024. PMID: 39682239 Free PMC article.
Theragnostic Gadolinium-Based Nanoparticles Safely Augment X-ray Radiation Effects in Patients with Cervical Cancer.
Chargari C, Maury P, Texier M, Genestie C, Morice P, Bockel S, Gouy S, Ba M, Achkar S, Lux F, Tillement O, Dufort S, Duc GLE, Debeaumont O, Massard C, Maulard A, Porcel E, Bahleda R, Ammari S, Morel D, Espenel S, Pautier P, Robert C, Deutsch E. Chargari C, et al. Among authors: bahleda r. ACS Nano. 2024 Jul 2;18(26):16516-16529. doi: 10.1021/acsnano.3c12537. Epub 2024 Jun 24. ACS Nano. 2024. PMID: 38912600 Clinical Trial.
Single-cell multiomics profiling reveals heterogeneous transcriptional programs and microenvironment in DSRCTs.
Henon C, Vibert J, Eychenne T, Gruel N, Colmet-Daage L, Ngo C, Garrido M, Dorvault N, Marques Da Costa ME, Marty V, Signolle N, Marchais A, Herbel N, Kawai-Kawachi A, Lenormand M, Astier C, Chabanon R, Verret B, Bahleda R, Le Cesne A, Mechta-Grigoriou F, Faron M, Honoré C, Delattre O, Waterfall JJ, Watson S, Postel-Vinay S. Henon C, et al. Among authors: bahleda r. Cell Rep Med. 2024 Jun 18;5(6):101582. doi: 10.1016/j.xcrm.2024.101582. Epub 2024 May 22. Cell Rep Med. 2024. PMID: 38781959 Free PMC article.
Reactions and adverse events induced by T-cell engagers as anti-cancer immunotherapies, a comprehensive review.
Géraud A, Hueso T, Laparra A, Bige N, Ouali K, Cauquil C, Stoclin A, Danlos FX, Hollebecque A, Ribrag V, Gazzah A, Goldschmidt V, Baldini C, Suzzoni S, Bahleda R, Besse B, Barlesi F, Lambotte O, Massard C, Marabelle A, Castilla-Llorente C, Champiat S, Michot JM. Géraud A, et al. Among authors: bahleda r. Eur J Cancer. 2024 Jul;205:114075. doi: 10.1016/j.ejca.2024.114075. Epub 2024 May 4. Eur J Cancer. 2024. PMID: 38733717 Review.
122 results